Professor John Snowden
BSc, MBChB, MD, FRCP (London), FRCP (Edin), FRCPath, DTM&H
Clinical Medicine, School of Medicine and Population Health
Honorary Professor
Consultant Haematologist
Director of Blood and Marrow Transplantation (BMT) Programme, 91探花 Teaching Hospitals NHS Foundation Trust.
+44 114 271 3357
Full contact details
Clinical Medicine, School of Medicine and Population Health
Royal Hallamshire Hospital
Glossop Road
91探花
S10 2JF
- Profile
-
For enquiries please contact - SMPH-West-Operational@sheffield.ac.uk
I trained as an undergraduate in the University of Leeds, and as a postgraduate in the UK, Australia and New Zealand. I have been Consultant Haematologist and Director of the Blood and Marrow Transplantation & Cellular Therapy Programme in 91探花 Teaching Hospitals NHS Foundation Trust, UK since 2002. I have recently been the Co-Lead Clinician for Haemato-Oncology of the North East & Yorkshire region Genomic Laboratory Hub (GLH), 2019-25. I am due to take up the post of Professor of Haematology at 91探花 in February 2025.
Nationally, I have held several key leadership roles in Blood and Marrow Transplantation (BMT) and Haemato-oncology, including Clinical Lead for various NICE Guidelines and Chair of the NHS England Clinical Reference Group for BMT (2016-20). From 2017-20, I was Chair of the Intercollegiate Committee on Haematology (ICH) to the Royal College of Physicians and Royal College of Pathologists. I was President of the British Society of Blood and Marrow Transplantation & Cellular Therapy (BSBMTCT) for 2021-22 and continued within the Board of Trustees as Past President (2023-24). In 2022, I was elected to the Board of Trustees of the British Society for Haematology (BSH).
Internationally, I have a long association with the European Society for Blood and Marrow Transplantation (EBMT) and the international accreditation organisation for transplant programmes, 鈥楯ACIE鈥, including JACIE Medical Director (2012-16) and Chair of the JACIE Committee (2015-20). I have served as a member of the EBMT Board and Scientific Council initially as Autoimmune Diseases Working Party Chair (2016-20) and as Secretary to EBMT from 2020-24.
Academically, I have contributed to the fields of BMT, haematology-oncology and autoimmunity with authorship of over 400 publications (Google Scholar h-index 74, with over 20,000 citations), along with clinical trials, grant awards, educational meetings, teaching, supervision, examination, journal editorship and scientific peer review. I have been awarded honorary professorships by 91探花 and University College London (UCL).
Current/recent appointments
- Consultant Haematologist & Director of Blood and Marrow Transplantation (BMT) Programme, 91探花 Teaching Hospitals NHS Foundation Trust, 2002-25.
- Honorary Professor, Division of Clinical Medicine, School of Medicine and Population Health, 91探花, UK, 2013-25.
- Honorary Clinical Professor, Department of Haematology, The Cancer Institute, UCL, 2016-25.
- Secretary to the European Society for Blood and Marrow Transplantation (EBMT), 2020-24.
- President of British Society of Blood and Marrow Transplantation & Cellular Therapy (BSBMTCT), 2021-22.
- Chair of the Intercollegiate Committee on Haematology (ICH) to the RCP (London) and RCPath, 2017-20.
- Co-Lead Clinician for Haematology-Oncology in the NHS England Genomic Laboratory Hub (GLH) for North-East & Yorkshire (NEY) region, 2019-25.
- British Society for Haematology (BSH), Elected Member of Board of Trustees, 2022-25.
- Qualifications
-
- BSc Pathology, First Class Honours, University of Leeds, 1987.
- Willis Prize in Pathology, University of Leeds 1987.
- MBChB Medicine, University of Leeds, 1989.
- Paul Fitton Prize in Anaesthesia, Association of Anaesthetists, UK 1988.
- Pullen Prize in Obstetrics and Gynaecology, University of Leeds 1989.
- William MacAdam Prize in Medicine, University of Leeds 1989.
- Membership of the Royal College of Physicians, MRCP (UK), 1992.
- Membership of the Royal College of Pathologists, MRCPath, 1999.
- Doctor of Medicine, MD, University of Leeds, 1999.
- Specialist Certification in Haematology, 1999.
- Fellowship of the Royal College of Physicians of London, FRCP (Lond), 2004.
- Fellowship of the Royal College of Pathologists, FRCPath, 2007.
- Fellowship of the Royal College of Physicians of Edinburgh, FRCP (Edin), 2019.
- Diploma in Tropical Medicine & Hygiene, DTM&H, awarded by RCP London 2021.
- BSc Pathology, First Class Honours, University of Leeds, 1987.
- Research interests
-
In conjunction with NHS roles, my principal academic areas of interest are:
- Blood and marrow stem cell transplantation in cancer and non-malignant disorders.
- Physical and psychological late effects in survivors of cancer treatment and BMT.
- Multiple myeloma, from cell biology to supportive care and survivorship research.
- Leukaemia and other haematological cancers.
- Service development, 鈥榪uality鈥, accreditation, benchmarking and health economics in haemato-oncology and BMT.
My academic activity is reflected by:
- Full publication of over 400 medical & scientific articles, with Google Scholar citation h-index of 74 and over 20,000 total citations.
- Over 拢10 million in grant awards as co-applicant or chief/principal investigator.
- Organising numerous national and international conferences.
- Regular invitations to speak and chair sessions at numerous national & international meetings.
- Extensive scientific peer review for respected general and specialist journals.
- Collaborations with other national and international Haemato-oncology and BMT Programmes.
- Principal Investigator/Chief Investigator roles in multicentre National Institute for Health Research (NIHR), National Cancer Research Institute (NCRI), investigator-led and industry sponsored clinical research trials.
- Delivering undergraduate/postgraduate teaching, supervision, training, examination in 91探花 Teaching Hospitals, 91探花 and 91探花 Hallam University.
- External examiner for PhD examinations in other Universities (Birmingham, Newcastle, Oxford).
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- . The Lancet Haematology, 11(12), E916-E926.
- . The Lancet Gastroenterology and Hepatology.
- . Nature Medicine, 29(7), 1760-1774.
- . Blood Journal.
- . Bone Marrow Transplantation.
- . British Journal of Haematology.
- . Bone Marrow Transplantation, 57(10), 1507-1513.
- . Bone Marrow Transplantation.
- . Annals of Oncology, 33(3), 259-275.
- . Bone Marrow Transplantation, 55(4), 681-694.
- . JAMA - Journal of the American Medical Association, 321(2), 165-174.
- . Bone Marrow Transplant.
- . British Journal of Haematology, 176(6), 888-907.
- . BMJ, e061514-e061514.
- . Bone Marrow Transplantation.
All publications
Books
Journal articles
- . The Lancet Haematology, 11(12), E916-E926.
- . Blood, 144(Supplement 1), 7848-7848.
- . Blood, 144(Supplement 1), 2379-2379.
- . Blood, 144(Supplement 1), 4733-4733.
- . Blood, 144(Supplement 1), 4894-4894.
- . The Lancet Haematology, S2352-3026(24)00249.
- . Clinical Lymphoma Myeloma and Leukemia, 24, S37-S38.
- . Annals of Neurology.
- . Best Practice & Research Clinical Haematology, 101556-101556.
- . HemaSphere, 8(6).
- . The Lancet Rheumatology, 6(6), e339-e351.
- . Journal of Allergy and Clinical Immunology: Global, 100283-100283.
- . Neurology, 102(17_supplement_1).
- . Bone Marrow Transplantation.
- . Efficacy and Mechanism Evaluation, 11(3).
- . eClinicalMedicine, 69, 102476-102476.
- . The Lancet Gastroenterology and Hepatology.
- . BMJ Open, 14(2), e083582-e083582.
- . Cytotherapy.
- . British Journal of Haematology.
- , 279-294.
- , 249-258.
- . Blood, 142(Supplement 1), 473-473.
- . Blood, 142(Supplement 1), 3403-3403.
- . Blood, 142(Supplement 1), 783-783.
- . Blood, 142(Supplement 1), 785-785.
- . Blood, 142(Supplement 1), 708-708.
- . Journal of Hepatology.
- . Nature Medicine, 29(7), 1760-1774.
- . Bone Marrow Transplant.
- . Blood Journal.
- . Annals of the Rheumatic Diseases, 82(Suppl 1), 964.2-965.
- . Haematologica.
- . JAMA Neurology, 80(7), 702-713.
- . Journal of Autoimmunity, 136.
- . Bone Marrow Transplantation.
- . Haematologica.
- . Journal of Allergy and Clinical Immunology.
- . Frontiers in Hematology, 2.
- . Bone Marrow Transplantation.
- . Bone Marrow Transplantation.
- . British Journal of Haematology.
- . Bone Marrow Transplantation.
- . Journal of Infection, 86(1), 1-8.
- . Transplantation and Cellular Therapy.
- . Blood, 140(Supplement 1), 10434-10436.
- . Blood, 140(Supplement 1), 2110-2112.
- . Blood, 140(Supplement 1), 6125-6126.
- . Journal of Allergy and Clinical Immunology, 150(6), 1289-1301.
- . Haematologica.
- . Frontiers in Oncology, 12.
- . Bone Marrow Transplantation, 57(10), 1507-1513.
- . Br J Haematol.
- . Journal of Neurology Neurosurgery & Psychiatry, 93(6), a19.2-a1a19.
- . Bone Marrow Transplantation.
- . Bone Marrow Transplant.
- . Bone Marrow Transplant.
- . Journal of Clinical Pathology.
- . British Journal of Haematology, 198(1), 24-45.
- . Bone Marrow Transplantation, 57, 742-752.
- . Bone Marrow Transplantation, 57(4), 633-640.
- . Bone Marrow Transplantation, 57(3), 343-346.
- . Frontiers in Immunology, 12.
- . Transplantation and Cellular Therapy.
- . Annals of Oncology, 33(3), 259-275.
- . Transplantation and Cellular Therapy, 28(6), 335.e1-335.e17.
- . Haematologica, 107(5), 1045-1053.
- . Blood Advances, 5(21), 4500-4503.
- . Frontiers in Oncology, 11.
- . Bone Marrow Transplant.
- . Bone Marrow Transplantation, 56(12), 2876-2881.
- . Bone Marrow Transplantation.
- . Am J Hematol.
- . Physiotherapy, 113, 88-99.
- . Bone Marrow Transplantation, 56, 1493-1508.
- . Vaccine, 39(34), 4778-4783.
- . Br J Dermatol.
- . Frontiers in Immunology, 12.
- . Bone Marrow Transplant.
- . Frontiers in Immunology, 12.
- . Bone Marrow Transplantation, 56(7), 1651-1664.
- . Br J Haematol.
- . Multiple Sclerosis Journal.
- . British Journal of Haematology, 192(3), 467-473.
- . PLOS Medicine, 18(1).
- . Supportive Care in Cancer, 29(2), 1145-1145.
- . Annual Review of Medicine, 72(1), 215-228.
- . Bone Marrow Transplantation, 56(3), 673-678.
- . Frontiers in Neurology, 11.
- . La Revue de M茅decine Interne, 41, A72-A73.
- . Blood, 136(Supplement 1), 11-13.
- . Blood, 136(Supplement 1), 3-4.
- . Blood, 136(Supplement 1), 39-40.
- . Blood, 136(Supplement 1), 18-19.
- . Blood, 136(Supplement 1), 32-33.
- COVID-19 and Stem Cell Transplantation; Results from the Prospective Survey By the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) and the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH). Blood, 136(20), 32-33.
- . Multiple Sclerosis and Related Disorders, 45, 102404-102404.
- . Annals of the Rheumatic Diseases, 79(Suppl 1), 385-385.
- . Acta Haematologica Polonica, 51(2), 73-80.
- . Bone Marrow Transplantation, 55(11), 2071-2076.
- . Frontiers in Immunology, 11.
- . Zeitschrift f眉r Rheumatologie, 79(5), 419-428.
- . Neurology, 94(15_supplement).
- . Neurology, 94(15_supplement).
- . Neurology, 94(15_supplement).
- . European Journal of Gastroenterology & Hepatology.
- . Rheumatology, 59(Supplement_2).
- . Bone Marrow Transplantation, 55(8), 1604-1613.
- . Nutrients, 12(1).
- . Bone Marrow Transplantation, 55(4), 838-839.
- . Haematologica, 105(2), 297-316.
- . Bone Marrow Transplantation, 55(7), 1473-1475.
- . Bone Marrow Transplantation, 55(4), 796-803.
- . The Lancet Haematology, 7(1), e50-e60.
- . Bone Marrow Transplantation, 55(4), 681-694.
- . Bone Marrow Transplantation, 55(2), 393-399.
- . Bone Marrow Transplantation, 55(1), 126-136.
- . Bone Marrow Transplantation, 55(2), 307-316.
- . Bone Marrow Transplantation, 55(7), 1512-1515.
- . British Journal of Haematology, 190(2).
- . BMC Gastroenterology, 19(1).
- . Blood, 134(Supplement_1), 3338-3338.
- . Blood, 134(Supplement_1), 4483-4483.
- . Blood, 134(Supplement_1), 3313-3313.
- . Blood, 134(Supplement_1), 4574-4574.
- . Blood, 134(Supplement_1), 2746-2746.
- . PLOS Medicine, 16(11).
- . Current Opinion in Supportive and Palliative Care, 13(4), 394-401.
- . Bone Marrow Transplantation, 54(10), 1525-1552.
- . Bone Marrow Transplantation.
- . British Journal of Haematology, 187(3).
- . EClinicalMedicine, 15, 33-41.
- . Hematology/Oncology and Stem Cell Therapy.
- . Expert Review of Clinical Immunology, 15(10), 981-985.
- . American Journal of Hematology, 94(11).
- . The Lancet Haematology, 6(11), e573-e584.
- . Journal of Clinical Oncology, 37(19), 1617-1628.
- . Biology of Blood and Marrow Transplantation, 25(10), 2079-2085.
- . HemaSphere, 3, 38-39.
- . Biology of Blood and Marrow Transplantation, 25(12), 2322-2329.
- . Journal of Huntington's Disease, 8(2), 181-193.
- . Current Hematologic Malignancy Reports, 14(2), 136-136.
- . Current Hematologic Malignancy Reports, 1-9.
- . British Journal of Haematology, 185(3), 450-467.
- . Bone Marrow Transplantation, 1-11.
- . Bone Marrow Transplantation, 1-10.
- . JAMA - Journal of the American Medical Association, 321(2), 165-174.
- . Vaccine, 37(3), 452-457.
- . British Journal of Haematology.
- . Current Research in Translational Medicine, 67(3), 79-88.
- . American Journal of Hematology, 94(1), 80-86.
- . Cytometry Part B: Clinical Cytometry, 96(3), 201-208.
- . Bone Marrow Transplantation, 54(6), 810-820.
- . Supportive Care in Cancer, 27(5), 1755-1763.
- . Bone Marrow Transplantation, 54(2), 173-174.
- . Trials, 19(1).
- . Blood, 132(Supplement 1), 2070-2070.
- . Blood, 132(Supplement 1), 3213-3213.
- . Journal of Bone and Mineral Research.
- . BMC Medical Informatics and Decision Making, 18(1).
- . Journal of Neurology, Neurosurgery & Psychiatry, 89(10), A28.2-A28.
- . Journal of Crohn's and Colitis, 12(9), 1097-1103.
- . Bone Marrow Transplantation, 53(9), 1139-1148.
- Bone Research Society Abstracts. JBMR plus, 2(Suppl ), 1-50.
- . BMJ Open, 8(8), e021222-e021222.
- . Clinical Medicine, 18(4), 329-334.
- . Biology of Blood and Marrow Transplantation, 24(11), 2265-2270.
- . Journal of Autoimmunity, 92, 35-46.
- . Bone Marrow Transplantation, 53(12), 1548-1552.
- . Frontiers in Immunology, 9.
- . Journal of Crohn's and Colitis, 12(4), 476-488.
- . BMJ Open, 8.
- . Clinical Infectious Diseases, 67(4), 564-572.
- . Haematologica, 103(5), 890-897.
- . Journal of Crohn's and Colitis, 12(supplement_1), S014-S015.
- . Journal of Crohn's and Colitis, 12(supplement_1), S070-S071.
- . Cytotherapy, 20(3), 453-460.
- . Calcified Tissue International, 102(2), 196-209.
- . Blood Advances, 1(27), 2742-2755.
- . Blood, 130(Suppl_1), 668-668.
- . Bone Marrow Transplantation, 52(12), 1588-1589.
- . Bone Marrow Transplantation, 52(12), 1674-1677.
- . Bone Marrow Transplantation, 52(7), 1082-1082.
- . Journal of Clinical Apheresis.
- . Haematologica, 102, e336-e339.
- . Br J Haematol.
- . Bone Marrow Transplantation.
- . Bone Marrow Transplantation, 52, 889-894.
- . J Clin Pathol.
- . Br J Haematol.
- . Brain, 140(4), 953-966.
- . Bone Marrow Transplant.
- . Bone Marrow Transplantation.
- . Bone Marrow Transplant.
- . British Journal of Haematology, 176(6), 888-907.
- . Leukemia.
- . BMJ Open, 7(3).
- . British Journal of Haematology.
- . Clinical Lymphoma Myeloma and Leukemia, 17(1), e23-e23.
- . Bone Marrow Transplant.
- . British Journal of Haematology, 176(1), 139-141.
- . Science, 358(6363), 602.1-602.
- . European Journal of Cancer Care.
- . Expert Opin Biol Ther.
- . Bone Marrow Transplantation.
- . The Lancet Haematology, 3(7), e340-e351.
- . Biology of Blood and Marrow Transplantation, 22(6), 1009-1016.
- . Bone Marrow Transplantation, 51(6), 889-889.
- . Current Research in Translational Medicine, 64(2), 71-82.
- . Hematology, 21(5), 272-279.
- . Biology of Blood and Marrow Transplantation, 22(8), 1493-1503.
- . Psycho-Oncology, 25(4), 400-411.
- . Nature Communications, 7(1), 10933-10933.
- . Blood, 127(1), 8-10.
- . British Journal of Haematology, 172(3), 478-481.
- . Bone Marrow Transplant, 51(4), 501-505.
- . British Journal of Haematology, 172(3), 360-370.
- . British Journal of Haematology, 172(2), 187-207.
- . Biology of Blood and Marrow Transplantation, 22(2), 385-390.
- . Clinical Endocrinology, 84(2), 296-304.
- . Blood, 126(23), 394-394.
- . EBioMedicine, 2(12), 2101-2109.
- . Clinical Lymphoma Myeloma and Leukemia, 15, e129-e130.
- . British Journal of Haematology, 171(1), 1-10.
- . British Journal of Cancer, 113(3), 365-371.
- . PLOS ONE, 10(7).
- . The Lancet, 385, S98-S98.
- . Bone Marrow Transplantation, 50(2), 173-180.
- . Journal of Clinical Pathology, 68(4), 292-300.
- . British Journal of Haematology, 168(1), 26-37.
- . Bone Marrow Transplantation, 50(2), 216-220.
- . Supportive Care in Cancer, 23(3), 671-678.
- . British Journal of Haematology, 167(1), 131-133.
- . British Medical Bulletin, 111(1), 117-138.
- . Bone Marrow Transplantation, 49(11), 1442-1443.
- . Bone Marrow Transplant.
- . QJM, 107(11), 871-877.
- . Support Care Cancer, 22(10), 2615-2620.
- . Bone Marrow Transplant, 49(7), 907-912.
- . Critical Care, 18(Suppl 1), P41-P41.
- . The Lancet Oncology.
- . International Journal of Laboratory Hematology.
- . Journal of Antimicrobial Chemotherapy, 69(1), 1-11.
- . Eur J Cancer Care (Engl), 23(3), 349-362.
- . Bone Marrow Transplant, 49(1), 42-48.
- . PLoS One, 9(5), e96474.
- . Blood, 122(21), 4640-4640.
- . Blood, 122(21), 3394-3394.
- . Blood, 122(21), 3378-3378.
- . Blood, 122(21), 765-765.
- . Blood, 122(21), 1884-1884.
- . Nature Genetics.
- . Ann Oncol, 24(9), 2430-2434.
- Superior response durability following a second autologous stem cell transplant (ASCT) for relapsed multiple myeloma (MM): results from the BSBMT/UKMF myeloma X (Intensive) trial. BRITISH JOURNAL OF HAEMATOLOGY, 161, 8-8.
- . Biology of Blood and Marrow Transplantation, 19(4), 666-669.
- . J Pain Symptom Manage, 46(5), 671-680.
- . Clinical and Experimental Immunology, 171(2), 201-209.
- . Lancet, 381(9872), 1081-1083.
- . British Journal of Haematology.
- . Journal of Autoimmunity.
- . International Journal of Laboratory Hematology.
- . J Neurol, 260(3), 914-916.
- . La Revue de M茅decine Interne, 33, A79-A80.
- . Nephron - Clinical Practice, 120(4).
- . Bone Marrow Transplantation, 47(6), 770-790.
- . Br J Haematol, 158(3), 419-420.
- . Br J Haematol, 157(6), 742-746.
- Using the clinical microsystems approach to enable ambulatory care to be a treatment option for patients with haematological malignancies. BONE MARROW TRANSPLANTATION, 47, S459-S459.
- . BMJ Supportive & Palliative Care, 2(Suppl 1), A3.2-A3.
- . British Journal of Haematology.
- . British Journal of Haematology, 156(2), 289-291.
- . Blood, 119(14), 3361-3369.
- . British Journal of Haematology, 157(6), 742-746.
- . Eur J Cancer Care (Engl), 21(1), 52-58.
- . QJM, 105(4), 369-371.
- . Blood, 118(21), 52-52.
- . Blood, 118(21), 324-324.
- . Br J Haematol, 154(1), 76-103.
- . Blood, 118(6), 1693-1698.
- . BMJ, 342(7802).
- . British Journal of Haematology, 153(5), 666-668.
- . Cellular Therapy and Transplantation, 3(10).
- Guidelines for the diagnosis and management of multiple myeloma 2011. British Journal of Haematology.
- . British Journal of Haematology, 154(1), 32-75.
- . Blood, 116(21), 2322-2322.
- . Haematologica, 95(10), 1783-1787.
- . Bone, 47, S189-S190.
- . Journal of Clinical Oncology, 28(15_suppl), 8060-8060.
- Relapse of Hodgkin's lymphoma (HL) after autologous stem cell transplantation (ASCT): Prognostic factors in 462 patients registered in the database of the EBMT. JOURNAL OF CLINICAL ONCOLOGY, 28(15).
- . Gastroenterology, 138(5), S-570.
- . BRIT J HAEMATOL, 149(2), 298-299.
- . Cancer, 116(6), 1592-1601.
- . Science, 328(5980), 825-826.
- . Blood, 116(16), 3080-3088.
- . Bone Marrow Transplant, 45(6), 1014-1021.
- . HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95(6), 989-995.
- . Br J Cancer, 101(4), 568-574.
- . Br J Cancer, 101(4), 561-567.
- Autologous stem cell transplant for severe refractory Crohn's disease: The UK experience. BONE MARROW TRANSPLANTATION, 43, S275-S275.
- A novel resistant FIP1L1-PDGFRa mutation in acute myeloid leukaemia, resistance to imatinib mesylate and allogeneic haemopoietic stem cell transplantation. BONE MARROW TRANSPLANTATION, 43, S96-S97.
- Immediate plasma removal and cryopreservation in HAS/DMSO corrects reduced CD34+cell viability in cryopreserved cell harvests from patients with systemic amyloidosis. BONE MARROW TRANSPLANTATION, 43, S107-S107.
- . J Bone Miner Res, 24(3), 425-436.
- . Transfusion Medicine, 19(4), 159-171.
- . British Journal of Haematology, 146(2), 225-227.
- . Transfusion Medicine, 19(5), 223-234.
- . CLINICAL ONCOLOGY, 20(10), 769-771.
- . Autoimmunity, 41(8), 625-631.
- . Blood, 112(11), 2391-2391.
- Outcomes of Patients with Haematological Malignancies Admitted to Either High Dependency Unit (HDU) or Intensive Care Unit (ICU) with or without Haemopoeitic Stem Cell Transplantation (HSCT): Analysis of Prognostic Factors for Survival. BLOOD, 112(11), 833-834.
- . Hum Reprod, 23(11), 2506-2512.
- . British Journal of Haematology, 142(3), 486-487.
- . Bone Marrow Transplantation, 42(9), 631-633.
- . British Journal of Haematology, 140(1), 113.
- . Blood, 110(11), 1055-1055.
- . Blood, 110(11), 326-326.
- . Bone Marrow Transplant, 40(10), 1003-1004.
- . J Clin Endocrinol Metab, 92(9), 3476-3482.
- . Hematology, 12(3), 179-191.
- . J Cancer Surviv, 1(1), 75-86.
- . British Journal of Haematology, 139(3), 429-433.
- . Biol Blood Marrow Transplant, 12(12), 1310-1317.
- . BRIT J HAEMATOL, 134(4), 385-390.
- . British Journal of Haematology, 134(6), 646.
- . Bone Marrow Transplantation, 38(4), 317-318.
- . Arthritis and Rheumatism, 54(12), 3750-3760.
- . Blood, 106(11), 641-641.
- Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. NEW ENGL J MED, 353(1), 33-45.
- . British Journal of Haematology, 128(4), 432-459.
- . Bone Marrow Transplantation, 35(9), 869-879.
- . Arthritis Res Ther, 7(1), R80-R92.
- Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: A report from the EBMT and ABMTR. J RHEUMATOL, 31(3), 482-488.
- . Bone Marrow Transplantation, 34(9), 745-751.
- . Blood, 102(8), 3043-3051.
- . Bone Marrow Transplant, 32 Suppl 1, S49-S51.
- . Bone Marrow Transplant, 32 Suppl 1, S53-S56.
- . Arthritis & Rheumatism, 48(5), 1463-1464.
- . Arthritis & Rheumatism, 48(5), 1464-1466.
- . ARTHRITIS AND RHEUMATISM, 48(5), 1464-1466.
- . ARTHRITIS RHEUM, 46(9), 2301-2309.
- . Clinical Science, 103(s47), 33P-33P.
- . Int Immunopharmacol, 2(4), 399-414.
- . Bone Marrow Transplantation, 29(6), 541-542.
- . Arthritis and Rheumatism, 46(3), 837-839.
- High dose therapy and autologous hemopoietic stem cell transplantation in rheumatoid arthritis--the feasibility of phase III trials.. J Rheumatol Suppl, 64, 55-59.
- Autologous stem cell transplantation for rheumatoid arthritis--interim report of 6 patients.. J Rheumatol Suppl, 64, 21-24.
- Considerations in the selection of an appropriate conditioning regimen for the treatment of rheumatoid arthritis by autologous peripheral blood stem cell transplantation.. J Rheumatol Suppl, 64, 39-41.
- . Bone Marrow Transplant, 28(1), 1-12.
- Long-term follow-up of highly selected autologous stem cell transplantation in severe rheumatoid arthritis with studies of synovial response and peripheral blood lymphocyte (PBL) reconstitution. RHEUMATOLOGY, 40, 83-83.
- . British Journal of Haematology, 113(3), 840-841.
- . Japanese Journal of Clinical Immunology, 23(6), 490-493.
- . RHEUMATOLOGY, 39(6), 681-682.
- . GUT, 46(6), 869-872.
- . Br J Haematol, 109(3), 641-643.
- . Japanese Journal of Clinical Immunology, 23(4), 257-260.
- . Bone Marrow Transplantation, 25(1), 119-120.
- . Annals of Medicine, 32(9), 615-621.
- . Bone Marrow Transplantation, 26(3), 309-313.
- A phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis. Arthritis and Rheumatism, 42(11), 2286-2292.
- . Bone Marrow Transplant, 24(7), 729-734.
- PBCST for rheumatoid arthritis - An Australian experience.. EXPERIMENTAL HEMATOLOGY, 27(7), 132-132.
- . Rheumatology, 38(4), 321-324.
- . The Lancet, 353(9150), 411-411.
- . Current Opinion in Rheumatology, 11(3), 167-172.
- . The Lancet, 353(9150), 410-411.
- . GASTROENTEROLOGY, 115(4), 1035-1036.
- A pilot dose escalation of high dose cyclophosphamide (CY) and autologous stem cell therapy (ASCT) in active rheumatoid arthritis (RA).. ARTHRITIS AND RHEUMATISM, 41(9), S132-S132.
- Autografting in severe active rheumatoid arthritis (RA) - Mobilisation and dose escalation studies. BRITISH JOURNAL OF HAEMATOLOGY, 101, 70-70.
- Haemopoietic stem cell (HSC) mobilisation with filgrastim in severe active rheumatoid arthritis (RA). BONE MARROW TRANSPLANTATION, 21, S51-S51.
- High dose cyclophosphamide (Cy) with autologous stem cell rescue in severe active rheumatoid arthritis (RA) - A dose escalation study. BONE MARROW TRANSPLANTATION, 21, S52-S52.
- Long-term outcome of autoimmune disease following allogeneic bone marrow transplantation. Arthritis and Rheumatism, 41(3), 453-459.
- . Bone Marrow Transplantation, 22(11), 1035-1041.
- . British Journal of Haematology, 103(3), 601-609.
- Haemopoietic stem cell transplantation (HSCT) for rheumatoid arthritis (RA). Experimental Hematology, 25(8), 902.
- . Arthritis & Rheumatism, 40(9), 1712-1715.
- A randomised, blinded, placebo controlled, pilot phase 1 study of the tolerability of filgrastim in patients with severe active rheumatoid arthritis for the mobilisation of peripheral blood progenitor cells.. ARTHRITIS AND RHEUMATISM, 40(9), 131-131.
- Haemopoietic stem cell transplantation (HSCT) for rheumatoid arthritis (RA). EXPERIMENTAL HEMATOLOGY, 25(8), 611-611.
- . Bone Marrow Transplantation, 20(1), 71-73.
- . Bone Marrow Transplantation, 19(12), 1247-1250.
- . Clin Lab Haematol, 19(2), 143-148.
- . British Journal of Haematology, 99(1), 9-22.
- . British Journal of Dermatology, 137(1), 130-132.
- . Pathology, 29(2), 221-223.
- . Journal of Clinical Pathology, 50(1), 67-70.
- . British Journal of Haematology, 98(1), 96-102.
- . Aust N Z J Med, 26(6), 852-853.
- . Lancet, 348(9035), 1112-1113.
- The microvasculature in myeloproliferative disease. A study using retinal fluorescein angiography. Clinical and Laboratory Haematology, 18(4), 277-279.
- . Clinical & Laboratory Haematology, 17(1), 95-96.
- . British Journal of Dermatology, 132(2), 283-285.
- . LANCET, 344(8933), 1361-1361.
- . BRITISH MEDICAL JOURNAL, 309(6955), 671-671.
- . CLINICAL INFECTIOUS DISEASES, 19(3), 547-548.
- . BMJ, 308(6928), 595-595.
- HUMAN PARVOVIRUS B19 - VIRUS TRANSMISSIBLE IN BLOOD PRODUCTS. BRITISH MEDICAL JOURNAL, 308(6928), 595-595.
- Dilatation of the colon complicating acute self-limited colitis.. QJM, 87(1), 55-62.
- . Postgraduate Medical Journal, 70(830), 921-923.
- Reversal of diabetes associated with escape of myeloma: Evidence for inappropriate IGF-II secretion. British Journal of Haematology, 87(1), 202-204.
- . QJM, 87(1), 55-62.
- . Postgraduate Medical Journal, 70(830), 924-926.
- APLASTIC-ANEMIA AND REMOXIPRIDE. LANCET, 342(8881), 1245-1245.
- . The Lancet, 342(8881), 1244-1245.
- . Br J Dermatol, 129(3), 250-256.
- . Journal of Infection, 27(3), 285-289.
- . BRITISH MEDICAL JOURNAL, 305(6848), 314-314.
- . Maturitas, 11(4), 348.
- . J Pathol, 159(1), 59-65.
- . Histopathology, 14(4), 369-379.
- . Bone Marrow Transplantation.
- . British Journal of Haematology.
- . eJHaem.
- . American Journal of Hematology.
- . Bone Marrow Transplantation.
- . Bone Marrow Transplantation.
- . Cytometry Part B: Clinical Cytometry.
- . Bone Marrow Transplantation.
- . Bone Marrow Transplantation.
- . British Journal of Haematology.
- . Blood Journal.
- . Haematologica.
- . Journal of Human Nutrition and Dietetics.
- . Bone Marrow Transplantation.
- . Haematologica.
- . Journal of Neurology, Neurosurgery & Psychiatry.
- . Bone Marrow Transplantation.
- . Cancer Nursing Practice.
- . Blood Advances.
- . Bone Marrow Transplantation.
- . Nature Medicine.
- . Bone Marrow Transplantation.
- . Bone Marrow Transplantation.
- . Bone Marrow Transplantation.
- . Bone Marrow Transplantation.
- . Bone Marrow Transplantation.
- . American Journal of Hematology.
- . Practical Neurology.
- . Nutrients, 14(13), 2776-2776.
- . HemaSphere, 6, 1327-1328.
- . BMJ, e061514-e061514.
- . Haematologica, 108(2), 645-652.
- . Bone Marrow Transplantation.
- . Statistical Methods in Medical Research, 096228022210841-096228022210841.
- . Bone Marrow Transplantation.
- . Bone Marrow Transplantation.
- . Blood Advances.
- . Acta Haematologica Polonica, 52(4), 217-224.
- . Bone Marrow Transplantation.
- . Frontiers in Neurology, 12.
- . Bone Marrow Transplantation.
- . Expert Review of Neurotherapeutics.
- . Bone Marrow Transplantation.
- . Frontiers in Immunology, 11.
- . Bone Marrow Transplantation.
- . Bone Marrow Transplantation.
- . Frontiers in Immunology, 11.
- . Frontiers in Immunology, 11.
- . Haematologica, haematol.2019.230128-haematol.2019.230128.
- . Leukemia & Lymphoma, 1-4.
- . Frontiers in Immunology, 10.
- . Endocrine Abstracts.
- . PLOS ONE, 10(3), e0119546-e0119546.
- . Bone Marrow Transplantation.
- . Bone Marrow Transplantation.
Chapters
- , The EBMT Handbook (pp. 495-500). Springer International Publishing
- , The EBMT Handbook (pp. 825-836). Springer International Publishing
- , The EBMT Handbook (pp. 41-47). Springer International Publishing
- , The EBMT/EHA CAR-T Cell Handbook (pp. 225-227). Springer International Publishing
- , The EBMT/EHA CAR-T Cell Handbook (pp. 183-187). Springer International Publishing
- , Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases (pp. 300-309). CRC Press
- , Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases (pp. 271-281). CRC Press
- , Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases (pp. 252-263).
- , Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases (pp. 241-251).
- , Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases (pp. 204-212).
- , Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases (pp. 103-109). CRC Press
- , Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases (pp. 547-556).
- , Quality Management and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy (pp. C1-C2). Springer International Publishing
- , The EBMT Handbook (pp. 415-420). Springer International Publishing
- , The EBMT Handbook (pp. 35-40). Springer International Publishing
- Haematopoietic Stem Cell Transplantation In Thachil J & Hill Q (Ed.), Haematology in Critical Care- a Practical Handbook Wiley-Blackwell
- Autoimmune Diseases In Apperley J (Ed.), EBMT Handbook European School of Haematology
- Haemopoietic stem cell transplantation in severe rheumatoid arthritis 鈥 world results In Burt RK & Marmont AM (Ed.), Stem Cell Therapy for Autoimmune Disease
- Acute intestinal failure 鈥 malignancy, chemotherapy and haemopoietic stem cell transplantation, Intestinal failure Wisepress
- High dose therapy and blood stem cell transplantation for rheumatoid arthritis. In Emery P (Ed.), Rheumatology Highlights 1998-99 (pp. 42-50). Oxford: Health Press.
- High dose therapy and blood stem cell transplantation for autoimmune diseases. In Emery P (Ed.), Rheumatology Highlights 1997
Conference proceedings papers
- . Journal of Clinical Oncology, Vol. 42(10) (pp 1158-1168)
- Proteasome Inhibitor-Augmented Salvage Autologous Stem Cell Transplantation for First Relapse Management in Relapsed Multiple Myeloma. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, Vol. 24 (pp S37-S38)
- Real-world Effectiveness and Safety of Autologous Haematopoietic Stem Cell Transplantation in MS: the UK Experience in 363 patients treated during 2002-2023. MULTIPLE SCLEROSIS JOURNAL, Vol. 30(3) (pp 20-21)
- The impact of disease modifying treatment washout periods prior to autologous stem cell transplantation for multiple sclerosis: real-world experience at a large centre. MULTIPLE SCLEROSIS JOURNAL, Vol. 30(3) (pp 1073-1074)
- Effectiveness of autologous haematopoietic stem cell transplantation in comparison with immune-reconstitution therapies in relapsing-remitting MS. MULTIPLE SCLEROSIS JOURNAL, Vol. 30(3) (pp 1193-1196)
- WORLDWIDE NETWORK FOR BLOOD AND MARROW TRANSPLANTATION GLOBAL STUDY ON BASELINE CHARACTERISTICS/CLINICAL OUTCOMES IN MULTIPLE MYELOMA PATIENTS UNDERGOING ASCT, A STUDY OFF 61,725 PATIENTS. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 479-480)
- GRAFT CRYOPRESERVATION EFFECTS ON THE OUTCOMES OF ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTS IN PAEDIATRIC POPULATION: A MULTICENTRE UK STUDY. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 569-570)
- AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AUTOIMMUNE DISEASES AT ST VINCENTS HOSPITAL, SYDNEY-25 YEARS AND 159 PATIENTS: AN ANALYSIS OF DISEASE SPECIFIC OUTCOMES AND SAFETY. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 37-38)
- AUTOMATING OUTCOME ANALYSIS FOR SCT PATIENTS: THE YEARLY OUTCOME REVIEW TOOL. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 666-667)
- AUTOMATING OUTCOME ANALYSIS FOR SCT PATIENTS: THE YEARLY OUTCOME REVIEW TOOL. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 688-688)
- TOWARD A CLINICAL PHENOTYPE INSPIRED DIAGNOSIS OF AUTOIMMUNE MANIFESTATIONS IN VEXAS SYNDROME: A GUIDE TO UBA1-TESTING FOR THE GENERALIST. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 344-345)
- THE IMPACT OF PATIENT-REPORTED ETHNICITY ON HAEMATOPOIETIC CELL TRANSPLANT OUTCOME: THE UK EXPERIENCE. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 34-34)
- ANTITHYMOCYTE GLOBULIN - OR ALEMTUZUMAB-BASED GVHD PROPHYLAXIS IN REDUCED- INTENSITY CONDITIONING ALLO-HCT FOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CR1: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 58-59)
- LONG TERM OUTCOMES FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LIGHT CHAIN DEPOSITION DISEASE: A RETROSPECTIVE STUDY ON BEHALF OF THE CMWP OF THE EBMT. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 478-478)
- NON MYELOABLATIVE VERSUS REDUCED INTENSITY CONDITIONING FOR ALLO-HCT FROM SIBLING OR UNRELATED DONORS IN PATIENTS WITH AML=65YEARS. A STUDY FROM THE EBMT ALWP. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 155-156)
- OUTCOME OF SARS-COV2 INFECTION IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS FOR AUTOIMMUNE DISEASES. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 38-39)
- INTERNATIONAL DIFFERENCES IN BASELINE CHARACTERISTICS AND PRACTICE PATTERNS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA UNDERGOING UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 479-479)
- CURRENT USE OF ANDROGENS IN BONE MARROW FAILURE DISORDERS: A REPORT FROM THE SEVERE APLASTIC ANEMIA WORKING PARTY (SAAWP) OF THE EBMT. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 36-37)
- AUTOLOGOUS PERIPHERAL BLOOD STEM CELL MOBILISATION TECHNIQUES, CELL YIELDS AND PRACTICE VARIATION-BYCOUNTRY IN MYELOMA PATIENTS UNDERGOING FIRST AUTOLOGOUS STEM CELL TRANSPLANTS IN EBMT CENTRES (2012-2021). BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 602-603)
- MONITORING AND MANAGEMENT OF CMV AND EBV AFTER AUTOLOGOUS HAEMATOPOIETIC CELL TRANSPLANTATION FOR AUTOIMMUNE DISEASES: A SURVEY OF THE EBMT AUTOIMMUNE DISEASES WORKING PARTY (ADWP). BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 418-419)
- COMPLETION OF THE PILOT PROJECT EVALUATING THE BENEFIT OF ADDITIONAL SUPPORT IN HCT RESEARCH DATA MANAGEMENT ON BEHALF OF ANTHONY NOLAN AND BSBMTCT. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 682-683)
- NO EVIDENCE FOR IMPROVED OVERALL SURVIVAL OR PROGRESSION-FREE SURVIVAL IN MULTIPLE MYELOMA PATIENTS AGED 70-75 UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION COMPARED TO A NON-TRANSPLANT STRATEGY. BONE MARROW TRANSPLANTATION, Vol. 58(SUPP1) (pp 366-367)
- . Blood, Vol. 140(Supplement 1) (pp 5225-5227)
- . Blood, Vol. 140(Supplement 1) (pp 5799-5800)
- . Blood, Vol. 140(Supplement 1) (pp 2408-2410)
- . Blood, Vol. 140(Supplement 1) (pp 4839-4842)
- . Blood, Vol. 140(Supplement 1) (pp 7552-7554)
- Observational trends in GvHD data submissions: Do centres have a data collection process and is this responsible for submission improvements?. BONE MARROW TRANSPLANTATION, Vol. 57(SUPPL 1) (pp 460-461)
- Late complications after autologous HSCT for autoimmune diseases: a retrospective study from the EBMT autoimmune. BONE MARROW TRANSPLANTATION, Vol. 57(SUPPL 1) (pp 25-26)
- International differences in baseline characteristics and practice patterns in newly diagnosed multiple myeloma (MM) patients undergoing upfront autologous stem cell transplantation. BONE MARROW TRANSPLANTATION, Vol. 57(SUPPL 1) (pp 44-45)
- Impact of societal and healthcare infection control measures on incidence of non-sars-2-cov respiratory viral infections in HSCT in-patient admissions; a single uk centre experience. BONE MARROW TRANSPLANTATION, Vol. 57(SUPPL 1) (pp 272-273)
- Does graft cryopreservation affect the outcomes of allogeneic haematopoietic cell transplants? A UK multicentre case control study during COVID19 pandemic. BONE MARROW TRANSPLANTATION, Vol. 57(SUPPL 1) (pp 97-97)
- Association between vitamin d and GVHD biomarkers with response to immunosuppression and survival in acute GVHD: An exploratory study. BONE MARROW TRANSPLANTATION, Vol. 57(SUPPL 1) (pp 216-216)
- Effectiveness of autologous haematopoietic stem cell transplantation in comparison with natalizumab in progressive MS. MULTIPLE SCLEROSIS JOURNAL, Vol. 28(3_SUPPL) (pp 953-954)
- Comparative effectiveness of autologous haematopoietic stem cell transplantation with immune reconstitution therapies in relapsing-remitting MS. MULTIPLE SCLEROSIS JOURNAL, Vol. 28(3_SUPPL) (pp 619-621)
- Comparative effectiveness of autologous haematopoietic stem cell transplantation vs. fingolimod, ocrelizumab and natalizumab in relapsing-remitting MS. MULTIPLE SCLEROSIS JOURNAL, Vol. 28(3_SUPPL) (pp 11-14)
- A changing target - adapting ongoing autologous haematopoietic stem cell transplantation clinical trials to evolving clinical practice in the treatment of highly active relapsing remitting multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL, Vol. 28(3_SUPPL) (pp 843-843)
- . Oral
- Trends in Autologous Stem Cell Mobilisation Practices in Myeloma Patients in Ebmt Centers Between 2008 And 2017. BONE MARROW TRANSPLANTATION, Vol. 56(SUPPL 1) (pp 327-328)
- Change In IPSS-R Between Diagnosis And Transplant And Transplant Outcome in Patients With MDS. A Retrospective Analysis From The Chronic Malignancies Working Party. BONE MARROW TRANSPLANTATION, Vol. 56(SUPPL 1) (pp 141-142)
- Autologous Hematopoietic Cell Transplantation For Relapsed Multiple Myeloma Performed With Stem Cells Re-Mobilised Following A Prior AUTO-HCT - A Retrospective Study on Behalf of EBMT CMWP. BONE MARROW TRANSPLANTATION, Vol. 56(SUPPL 1) (pp 133-134)
- One Thousand Voices Address Patient Engagement in Hematopoietic Stem Cell Transplantation And Cell Therapy: Results of A Survey From The EBMT. BONE MARROW TRANSPLANTATION, Vol. 56(SUPPL 1) (pp 160-162)
- Building of The G0-CAR-T Initiative to Promote Use of Data Collected from Patients Treated With CAR-T Cells AT EU OR EBMT Affiliated Programs. BONE MARROW TRANSPLANTATION, Vol. 56(SUPPL 1) (pp 43-44)
- Genetic and genomic characterisation of older adults with acute lymphoblastic leukemia treated on the UKALL14 and UKALL60+clinical trials. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 189 (pp 58-58)
- Cancer, fertility and me: a NEW fertility preservation patient decision aid to support YOUNG women with breast cancer. BREAST CANCER RESEARCH AND TREATMENT, Vol. 180(2) (pp 578-578)
- Adenovirus Infections after HCT: Infectious Diseases Working Party Retrospective EBMT Registry Study. BONE MARROW TRANSPLANTATION, Vol. 55(SUPPL 1) (pp 467-468)
- Multiple sclerosis-like CNS inflammation following allogeneic haematopoietic stem cell transplantation treated with a 'domino' autologous haematopoietic stem cell transplantation. NEUROLOGY, Vol. 94(15)
- National Health Service England (NHSE) Program for Selection of Adult Primary Immunodeficiency Patients For Allogeneic Haematopoietic Stem Cell Transplantation. BONE MARROW TRANSPLANTATION, Vol. 55(SUPPL 1) (pp 104-105)
- The use of Autologous Haemopoetic Stem Cell Transplantation (aHSCT) in Multiple Sclerosis after Alemtuzumab Treatment Failure: A Case Series. BONE MARROW TRANSPLANTATION, Vol. 55(SUPPL 1) (pp 227-227)
- Beam vs Cyclophosphamide-Based Conditioning Regimen in Aggressive Multiple Sclerosis: A Retrospective Analysis of European Blood and Marrow Transplantation Society. BONE MARROW TRANSPLANTATION, Vol. 55(SUPPL 1) (pp 37-38)
- Autologous stem cell transplantation versus alemtuzumab or ocrelizumab in relapsing remitting multiple sclerosis (starms). MULTIPLE SCLEROSIS JOURNAL, Vol. 26(3_SUPPL) (pp 209-210)
- Autologous haematopoietic stem cell transplantation in multiple sclerosis and other immune-mediated neurological diseases: guidelines and recommendations of the European Society for Blood and Marrow Transplantation and the Joint Accreditation Committee of the International Society for Cellular Therapy. NEUROLOGY, Vol. 94(15)
- The use of Autologous Haemopoetic Stem Cell Transplantation (AHSCT) in Multiple Sclerosis after Alemtuzumab treatment failure: a case series. NEUROLOGY, Vol. 94(15)
- HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN SYSTEMIC SCLEROSIS: SHEFFIELD TEACHING HOSPITALS' EXPERIENCE. RHEUMATOLOGY, Vol. 59
- National Implementation of the use of Tisagenlecleucel in Paediatric and Young Adult Patients with Acute Lymphoblastic Leukaemia (ALL) in National Health Service England (NHSE). BONE MARROW TRANSPLANTATION, Vol. 55(SUPPL 1) (pp 228-229)
- Diagnosis and Management of Secondary HLH/MAS following HSCT and CAR-t Cell Therapy in Adults; An EBMT-wide Survey on Behalf of the ADWP and TCWP. BONE MARROW TRANSPLANTATION, Vol. 55(SUPPL 1) (pp 582-583)
- Autologous Stem Cell Transplantation in Behcet ' s Disease: A Retrospective Study. BONE MARROW TRANSPLANTATION, Vol. 55(SUPPL 1) (pp 224-225)
- GVHD and Relapse Free Survival (GRFS) After Allogeneic Transplantation for Idiopathic Severe Aplastic Anemia: An Analysis from the Saawp Data Quality Initiative Program of EBMT. BONE MARROW TRANSPLANTATION, Vol. 55(SUPPL 1) (pp 34-35)
- Outcome of Autologous Hematopoietic Stem Cell Transplantation for Refractory Takayasu Arteritis, A Retrospective Survey from the Autoimmune Diseases Working Party (ADWP) of the Ebmt. BONE MARROW TRANSPLANTATION, Vol. 55(SUPPL 1) (pp 226-227)
- Outcome of Haematopoietic Cell Transplantation in Children with Fanconi Anaemia: A Study on Behalf of the EBMT SAAWP and PDWP. BONE MARROW TRANSPLANTATION, Vol. 55(SUPPL 1) (pp 35-36)
- Tuberculosis After Hematopoietic Stem Cell Transplantation: Retrospective Study of Infectious Diseases Working Party EBMT. BONE MARROW TRANSPLANTATION, Vol. 55(SUPPL 1) (pp 110-112)
- Donor Factors Influence Outcomes of Patients Receiving Donor Lymphocyte Infusion for Mixed Chimerism after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation. BONE MARROW TRANSPLANTATION, Vol. 55(SUPPL 1) (pp 551-551)
- Survivorship Care for Allogeneic Transplant Patients in The UK: Current Service Provision and Barriers to Implementation. BONE MARROW TRANSPLANTATION, Vol. 55(SUPPL 1) (pp 618-619)
- Autologous Hematopoietic Stem Cell Transplantation for Behcet's Disease: A Retrospective Survey of Patients Treated in Europe, on the Behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Bone Marrow Transplantation. ARTHRITIS & RHEUMATOLOGY, Vol. 72
- THE CLINICAL IMPACT OF PERMISSIVE AND NON-PERMISSIVE HLA-DPB1 MISMATCHES IN HAEMOPOIETIC STEM CELL TRANSPLANTATION, A RETROSPECTIVE STUDY. HLA, Vol. 95(4) (pp 394-394)
- Donor EBV-positive serostatus increases the risk of chronic GVHD in patients with non-malignant hematological disorders: Infectious diseases working party EBMT study. BONE MARROW TRANSPLANTATION, Vol. 54 (pp 400-401)
- Allogeneic hsct for autoimmune diseases: A retrospective study from the ebmt autoimmune diseases, inborn errors and paediatric working parties. BONE MARROW TRANSPLANTATION, Vol. 54 (pp 33-34)
- Impact of early candidemia on the long-term outcome of allogeneic hematopoietic stem cell transplant in non leukemic patients: An outcome analysis on behalf of IDWP. BONE MARROW TRANSPLANTATION, Vol. 54 (pp 397-399)
- Young HLA-matched unrelated donors are comparable to matched sibling donors in elderly patients receiving reduced-intensity conditioning: an analysis on behalf of the EBMT scientific council. BONE MARROW TRANSPLANTATION, Vol. 54 (pp 602-603)
- HSCT treatment for multiple sclerosis: Results from the MIST trial. EUROPEAN JOURNAL OF NEUROLOGY, Vol. 26 (pp 978-978)
- Autologous haematopoietic stem cell transplantation for severe treatment resistant autoimmune diseases. HUMAN GENE THERAPY, Vol. 30(8) (pp A5-A5)
- Baseline Skin Score, Older Age and CD34-selection Influence the Outcome of Autologous Stem Cell Transplantation for Systemic Sclerosis - Results of a Prospective Non-interventional Study from the European Society for Blood & Marrow Transplantation (EBMT). ARTHRITIS & RHEUMATOLOGY, Vol. 71
- . Blood, Vol. 132(Supplement 1) (pp 251-251)
- . Blood, Vol. 132(Supplement 1) (pp 255-255)
- . Blood, Vol. 132(Supplement 1) (pp 3431-3431)
- . Blood, Vol. 132(Supplement 1) (pp 3425-3425)
- The use of autologous haematopoietic stem cell transplantation as a first line disease modifying therapy in patients with 'aggressive' multiple sclerosis.. MULTIPLE SCLEROSIS JOURNAL, Vol. 24 (pp 87-88)
- Experience of developing and evaluating a fertility preservation patient decision aid for teenage and adult women with cancer for use in oncology settings, UK (The Cancer, Fertility and Me study). PSYCHO-ONCOLOGY, Vol. 27 (pp 45-45)
- Lethal infectious complications after hematopoietic stem cell transplantation: progress and challenges in Infectious Diseases Working Party study. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 94-95)
- BEAM versus LEAM conditioning chemotherapy for autologous transplantation in lymphoma. A retrospective study from the BSBMT. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 258-258)
- Peripheral blood stem cell RIC haploidentical transplantation low incidence of GVHD and non relapse mortality: Preliminary results from the prospective phase II UK Haplo study. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 752-754)
- Should Donor Selection be Driven by Disease Risk? A Retrospective Analysis of the EBMT Registry on Behalf of the Acute Leukemia Working Party. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 135-136)
- Allogeneic stem cell transplantation in patients with CML-CP in the era of third generation tyrosine kinase inhibitors: a study by the CMWP of the EBMT. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 45-46)
- Autologous Haematopoietic Stem Cell Transplantation (AHSCT) for Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis (AAV): Results of a EBMT Retrospective Survey. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 203-204)
- Autologous Haematopoietic Stem Cell Transplantation (Auto-HSCT) in Stiff Person Syndrome (SPS): The 91探花 Experience. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 204-205)
- The use of Autologous Haematopoietic Stem Cell Transplantation in treatment naive patients with severe multiple sclerosis. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 38-39)
- Autologous Stem cell transplantation for progressive systemic sclerosis: an EBMT Autoimmune Disease Working Party prospective non-interventional approach. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 37-38)
- Infectious Diseases Working Party Retrospective Study on HHV-6 encephalitis: clinical characteristics and outcome after allogeneic HSCT. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 565-566)
- Is it feasible to conduct a randomised controlled trial of pre-habilitation in multiple myeloma (MM) patients awaiting autologous haematopoietic stem-cell transplantation (AHSCT)? The PREeMPT study. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 343-344)
- Vaccine preventable diseases: a clinical evaluation of antibody reconstitution after autologous HCT. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 381-382)
- Allogeneic stem cell transplantation in patients with CML-CP in the era of third generation tyrosine kinase inhibitors: a study by the CMWP of the EBMT. SWISS MEDICAL WEEKLY, Vol. 148 (pp 4S-4S)
- . Saturday, 16 JUNE 2018
- Autologous Haematopoietic Stem Cell Transplantation in Treatment Naive Patients with Rapidly Evolving Severe Multiple Sclerosis. NEUROLOGY, Vol. 90
- Non-myeloablative hematopoietic stem cell transplantation (HSCT) is superior to disease modifying drug (DMD) treatment in highly active Relapsing Remitting Multiple Sclerosis (RRMS): interim results of the Multiple Sclerosis International Stem cell Transplant (MIST) Randomized Trial. NEUROLOGY, Vol. 90
- Peripheral blood stem cell RIC haploidentical stem cell transplantation low TRM, low rates of GVHD: Preliminary results from the prospective Phase II single arm UK Haplo study (Bloodwise: 11034). BRITISH JOURNAL OF HAEMATOLOGY, Vol. 181 (pp 13-13)
- Autologous haematopoietic stem cell transplantation for Crohn's disease: a retrospective study from the European Society for Blood & Marrow Transplantation (EBMT) Autoimmune Diseases Working Party. JOURNAL OF CROHNS & COLITIS, Vol. 12 (pp S14-S15)
- ECCO-EBMT joint paper: autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn's disease: Summary of the ECCO-EBMT joint review. JOURNAL OF CROHNS & COLITIS, Vol. 12 (pp S70-S71)
- Use of haploidentical stem cell transplantation continues to increase, the 2015 European society for blood and marrow transplant activity survey report. BONE MARROW TRANSPLANTATION, Vol. 52 (pp S191-S192)
- Autologous haematopoietic stem cell transplantation (AHSCT) for Crohn's disease (CD): A retrospective study of outcomes from the EBMT autoimmune diseases working party (ADWP). BONE MARROW TRANSPLANTATION, Vol. 52 (pp S418-S418)
- Autologous stem cell transplantation for systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT. BONE MARROW TRANSPLANTATION, Vol. 52 (pp S440-S440)
- Application of the disease risk index for risk stratification of allogeneic hematopoietic stem cell transplantation in a large cohort of the European Society for Blood and Marrow Transplantation (EBMT). BONE MARROW TRANSPLANTATION, Vol. 52 (pp S12-S13)
- HSCT for adult cerebral adrenoleukodystrophy. BONE MARROW TRANSPLANTATION, Vol. 52 (pp S120-S120)
- EBV and CMV reactivation following autologous haematopoietic stem cell transplantation (HSCT) for autoimmune neurological diseases resolves spontaneously and rarely requires treatment. BONE MARROW TRANSPLANTATION, Vol. 52 (pp S419-S419)
- Viral microneutralization assay to determine seasonal influenza vaccine immunogenicity in the first year post reduced intensity conditioning allogeneic HSCT. BONE MARROW TRANSPLANTATION, Vol. 52 (pp S269-S270)
- Allogeneic HSCT for autoimmune diseases: a retrospective study from the EBMT autoimmune diseases, inborn errors and paediatric working parties. BONE MARROW TRANSPLANTATION, Vol. 52 (pp S42-S42)
- Evaluating the cost-effectiveness of autologous haematopoietic stem cell transplantation (aHSCT) versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison (MAIC). BONE MARROW TRANSPLANTATION, Vol. 52 (pp S41-S41)
- RESULTS FROM UKALL60+, A UK/HOVON COLLABORATIVE PHASE 2 STUDY IN ELDERLY PATIENTS WITH UNTREATED ACUTE LYMPHOBLASTIC LEUKAEMIA. HAEMATOLOGICA, Vol. 102 (pp 31-32)
- MESENCHYMAL STROMAL CELLS FOR THE TREATMENT OF STEROID-RESISTANT ACUTE GRAFT VERSUS HOST DISEASE: FACTORS INFLUENCING CLINICAL RESPONSES. HAEMATOLOGICA, Vol. 102 (pp 336-337)
- The impact of the BBC Panorama television programme on public awareness of autologous haematopoietic stem cell transplantation (AHSCT) for patients with multiple sclerosis. NEUROLOGY, Vol. 88
- . Blood, Vol. 128(22) (pp 988-988)
- . Blood, Vol. 128(22) (pp 628-628)
- . Blood, Vol. 128(22) (pp 2293-2293)
- . Blood, Vol. 128(22) (pp 4585-4585)
- . Blood, Vol. 128(22) (pp 2266-2266)
- The impact of the BBC Panorama television programme on public awareness of autologous haematopoietic stem cell therapy (AHSCT) for patients with multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL, Vol. 22 (pp 784-784)
- INITIAL RESULTS FROM UKALL60+, A UK/HOVON COLLABORATIVE PHASE 2 STUDY IN ELDERLY PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA. HAEMATOLOGICA, Vol. 101 (pp 34-34)
- The Use of Autologous Haemopoietic Stem Cell Transplantation in Treating Patients with Rapidly Evolving Severe Multiple Sclerosis. NEUROLOGY, Vol. 86
- The Use of Autologous Haemopoietic Stem Cell Transplantation in Treating Patients with Rapidly Evolving Severe Multiple Sclerosis. NEUROLOGY, Vol. 86
- High dose melphalan and autologous stem cell transplantation following urinary bladder reconstruction with ileum: Measures to minimise mucositis. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 173 (pp 178-178)
- A salvage autologous stem cell transplant (ASCT2) induces superior overall survival following bortezomib-containing re-induction therapy for relapsed multiple myeloma (MM): Results from the Myeloma X (Intensive) Trial. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 173 (pp 5-6)
- Mortality within 30 days of systemic anticancer therapy (SACT) - results of a multi-site audit following the NCEPOD model in the South Yorkshire region. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 173 (pp 34-34)
- Balancing therapeutic impact of treatment strategies with quality of life and pain experience in multiple myeloma: New insights into influence of genetic variants. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 173 (pp 132-133)
- Outcomes following salvage autologous stem cell transplant (ASCT2) vs low dose alkylating consolidation (non-transplant consolidation NTC) therapy following bortezomib-containing re-induction for relapsed multiple myeloma (MM) may be dependent on age and symptomatic status initiation of re-induction: Results from the Myeloma X (Intensive) Trial. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 173 (pp 165-165)
- Routine Vaccination Programme (RVP) Practice after Adult and Paediatric Allogeneic Haematopoietic Stem Cell Transplant (HSCT): A British Society of Blood and Marrow Transplantation (BSBMT) Survey of UK NHS-Based Programmes. BONE MARROW TRANSPLANTATION, Vol. 51 (pp S400-S401)
- Graft storage and disposal policies in a large group of european centers: a survey by the cellular therapy and immunobiology working party (CTIWP) of the European Group For Blood And Marrow Transplantation (EBMT). BONE MARROW TRANSPLANTATION, Vol. 51 (pp S50-S51)
- Comparison of Haematopoietic Stem Cell Transplantation Approaches in Primary Plasma Cell Leukaemia. BONE MARROW TRANSPLANTATION, Vol. 51 (pp S18-S19)
- . British Journal of Haematology, Vol. 172(3) (pp 482-486)
- ASCT2A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial. BLOOD, Vol. 126(23)
- . Blood, Vol. 126(23) (pp 1210-1210)
- . Blood, Vol. 126(23) (pp 1985-1985)
- . Blood, Vol. 126(23) (pp 1981-1981)
- . Blood, Vol. 126(23) (pp 3180-3180)
- . Journal of Neurology, Neurosurgery & Psychiatry, Vol. 86(11) (pp e4.116-e4)
- EBMT Autoimmune Diseases Working Party (ADWP) Database: Activity 1994-2014. BONE MARROW TRANSPLANTATION, Vol. 50 (pp S112-S112)
- Metabolic syndrome is common following haematopoietic cell transplantation (HCT) and is associated with increased cardiovascular disease: an EBMT cross-sectional non-interventional study. BONE MARROW TRANSPLANTATION, Vol. 50 (pp S89-S90)
- A retrospective IDWP-ALWP study on Candida infections in allogeneic haematopoietic stem cell transplant patients. BONE MARROW TRANSPLANTATION, Vol. 50 (pp S32-S33)
- CD34+count and not total nucleated cell count has impact on OS in adult dUCBT. BONE MARROW TRANSPLANTATION, Vol. 50 (pp 5566-5567)
- Autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a UK cohort from two centres. BONE MARROW TRANSPLANTATION, Vol. 50 (pp S61-S61)
- A study of adherence to a vaccination schedule following adult allogenic haematopoietic stem cell transplants in UK transplant centre. BONE MARROW TRANSPLANTATION, Vol. 50 (pp S203-S204)
- Implementing International HCT Late Effects Screening Guidelines in Clinical Practice: Outcomes. BONE MARROW TRANSPLANTATION, Vol. 50 (pp S210-S210)
- Provision of Long-term Monitoring and Late Effects Services Following Allogeneic HSCT in Adults: A British Society of Blood and Marrow Transplantation (BSBMT) Survey of UK NHS-Based Programmes. BONE MARROW TRANSPLANTATION, Vol. 50 (pp S91-S92)
- . Blood, Vol. 124(21) (pp 4577-4577)
- . Blood, Vol. 124(21) (pp 2517-2517)
- EFFECTS OF SINGLE-AGENT BORTEZOMIB (BTZ) AS POST-TRANSPLANT CONSOLIDATION ON MULTIPLE MYELOMA (MM)-RELATED BONE DISEASE: FIRST RESULTS FROM A MULTICENTER, RANDOMIZED PHASE 2 STUDY. HAEMATOLOGICA, Vol. 99 (pp 362-362)
- Stem cells harvested after bortezomib-based re-induction for multiple myeloma relapsing after autologous stem cell transplant (ASCT) and those stored from first induction yield equal outcomes: results from the BSBMT/UKMF Myeloma X (Intensive) Trial. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 165 (pp 62-63)
- The utility of minimal residual disease (MRD) assessment in post-first relapse re-induction: results from the BSBMT/UKMF Myeloma X (intensive) Trial. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 165 (pp 65-66)
- UK EXPERIENCE OF UNRELATED CORD BLOOD TRANSPLANTATION IN PAEDIATRIC PATIENTS. BONE MARROW TRANSPLANTATION, Vol. 49 (pp S359-S359)
- EVOLUTION, TRENDS AND LONG TERM OUTCOMES IN HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN AUTOIMMUNE DISEASES (ADS): A RETROSPECTIVE STUDY FROM THE AUTOIMMUNE DISEASES WORKING PARTY (ADWP) OF THE EBMT 1996-2013. BONE MARROW TRANSPLANTATION, Vol. 49 (pp S43-S43)
- UK EXPERIENCE OF UNRELATED CORD BLOOD TRANSPLANTATION (UCBT) IN ADULTS: A RETROSPECTIVE ANALYSIS ON BEHALF OF EUROCORD AND THE BRITISH SOCIETY OF BLOOD AND MARROW TRANSPLANTATION (BSBMT). BONE MARROW TRANSPLANTATION, Vol. 49 (pp S233-S234)
- STEM CELL HARVESTING AFTER RE-INDUCTION WITH A BORTEZOMIB-BASED REGIMEN FOR MULTIPLE MYELOMA RELAPSING AFTER AUTOLOGOUS STEM CELL TRANSPLANT IS FEASIBLE, SAFE AND EFFECTIVE: RESULTS FROM THE BSBMT/UKMF MYELOMA X (INTENSIVE) TRIAL. BONE MARROW TRANSPLANTATION, Vol. 49 (pp S73-S74)
- UPDATE OF THE ACTIVITY OF THE EBMT AUTOIMMUNE DISEASES WORKING PARTY (ADWP). BONE MARROW TRANSPLANTATION, Vol. 49 (pp S95-S96)
- SUPERIOR DURABILITY OF RESPONSE WHEN A SECOND AUTOLOGOUS STEM CELL TRANSPLANT CONSOLIDATES BORTEZOMIB-CONTAINING RE-INDUCTION THERAPY FOR RELAPSED MULTIPLE MYELOMA (MM): FINAL RESULTS FROM THE BSBMT/UKMF MYELOMA X (INTENSIVE) TRIAL. BONE MARROW TRANSPLANTATION, Vol. 49 (pp S72-S72)
- MINIMAL RESIDUAL DISEASE (MRD) ASSESSMENT IN POST-FIRST RELAPSE RE-INDUCTION IS PREDICTIVE FOR TIME TO PROGRESSION (TTP): RESULTS FROM THE BSBMT/UKMF MULTIPLE MYELOMA (MM) X INTENSIVE TRIAL. BONE MARROW TRANSPLANTATION, Vol. 49 (pp S79-S80)
- Mortality predictors in patients with haematological malignancies admitted to critical care. BRITISH JOURNAL OF ANAESTHESIA, Vol. 110(5) (pp 862-863)
- A second autologous stem cell transplant induces superior response durability following bortezomib-containing re-induction therapy for relapsed multiple myeloma: results from the BSBMT/UKMF myeloma x (intensive) trial. BONE MARROW TRANSPLANTATION, Vol. 48 (pp S17-S17)
- BSBMT/UKMF myeloma X relapse (intensive) trial: barriers to recruitment and randomization. BONE MARROW TRANSPLANTATION, Vol. 48 (pp S210-S211)
- Use of plerixafor to rescue absolute and predicted mobilization failures: a UK and Ireland consensus. BONE MARROW TRANSPLANTATION, Vol. 48 (pp S112-S113)
- BSBMT/UKMF Myeloma X Relapse (intensive) Trial - challenges in recruitment and randomisation. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 161 (pp 52-52)
- Comparative Effectiveness of Lenalidomide Plus Dexamethasone for the Treatment of Refractory/Relapsed Multiple Myeloma: A Systematic Review and Mixed Treatment Comparison. BLOOD, Vol. 120(21)
- Pulse high-dose cyclophosphamide in malignant multiple sclerosis may result in successful functional recovery and stem cell mobilisation to enable safe delivery of AHSCT. BONE MARROW TRANSPLANTATION, Vol. 47 (pp S227-S228)
- Predicting increases in bed capacity for haematopoietic stem cell transplantation or intensive chemotherapy through simulation modelling of ambulatory care. BONE MARROW TRANSPLANTATION, Vol. 47 (pp S278-S278)
- A STUDY OF THE CARDIORESPIRATORY LATE EFFECTS IN PATIENTS WITH ADVANCED INTENSIVELY TREATED MULTIPLE MYELOMA. HAEMATOLOGICA, Vol. 97 (pp 623-623)
- AZACITIDINE IS WELL TOLERATED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AND ITS ADMINISTRATION IS ASSOCIATED WITH A REDUCED RISK OF ACUTE GRAFT-VERSUS-HOST DISEASE. HAEMATOLOGICA, Vol. 97 (pp 21-22)
- . THORAX, Vol. 66 (pp A62-A62)
- Azacitidine Induces Expansion of Regulatory T Cells and Tumour Specific CD8+T Lymphocytes After Allogeneic Stem Cell Transplantation: A Strategy for Epigenetic Manipulation of a Graft-Versus-Leukemia Response. BLOOD, Vol. 118(21) (pp 152-152)
- National, Retrospective, Multi-Centre Comparison of Alemtuzumab- Versus ATG-Based Conditioning Regimens in Hematopoietic Stem Cell Transplantation for Aplastic Anemia: A Study From the British Society for Blood and Marrow Transplantation (BSBMT) (CTCR 09-03). BLOOD, Vol. 118(21) (pp 26-26)
- Umbilical cord blood transplantation (UCBT) in teenagers and adults: 91探花 experience 2005-2010. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 153 (pp 68-69)
- Endocrine, bone and nutritional 'late effects' in patients with advanced stage multiple myeloma following HSCT and other intensive treatment. BONE MARROW TRANSPLANTATION, Vol. 46 (pp S186-S186)
- Diagnosis of Lupus, age at HSCT and CD34+graft selection are the main risk factors for secondary autoimmune diseases occurring after HSCT for autoimmune diseases: a retrospective study of the EBMT Autoimmune Disease Working Party. BONE MARROW TRANSPLANTATION, Vol. 46 (pp S84-S85)
- Incidence and Risk Factors for Secondary Autoimmune Diseases (AD) After Hematopoietic Stem Cell Transplantation (HSCT) for a Severe Autoimmune Disease-A Retrospective EBMT WP AD Study. BLOOD, Vol. 116(21) (pp 959-960)
- RELAPSE OF HODGKIN'S LYMPHOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): IDENTIFICATION OF PROGNOSTIC FACTORS PREDICTING OUTCOME. HAEMATOLOGICA, Vol. 95 (pp S26-S26)
- Autologous peripheral progenitor cell harvesting in haematology patients: One centre experience. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 149 (pp 67-67)
- A study of pain, peripheral neuropathy and psychosocial late effects in patients with intensively treated advanced multiple myeloma. BONE MARROW TRANSPLANTATION, Vol. 45 (pp S396-S396)
- A study of the endocrine, metabolic and nutritional late effects in patients with advanced intensively treated multiple myeloma. BONE MARROW TRANSPLANTATION, Vol. 45 (pp S396-S397)
- CHOICE OF CONDITIONING REGIMEN. BONE MARROW TRANSPLANTATION, Vol. 45 (pp S3-S3)
- High-dose melphalan with stem cell rescue in the ambulatory care setting: the process to enable the concept to become a realistic treatment option. BONE MARROW TRANSPLANTATION, Vol. 43 (pp S319-S319)
- Quality of life in adult survivors of blood and marrow transplantation correlates strongly with physical and psychological late effects of treatment: a mixed methods approach. BONE MARROW TRANSPLANTATION, Vol. 43 (pp S180-S180)
- Bone marrow transplantation in adult cerebral X-linked adrenoleukodystrophy: an update. BONE MARROW TRANSPLANTATION, Vol. 43 (pp S182-S183)
- High-dose G-CSF is safe and effective for mobilisation of haemopoietic cells for autologous stem cell transplantation with clinical utility in the majority of sub-optimal mobilisers. BONE MARROW TRANSPLANTATION, Vol. 43 (pp S114-S115)
- PATIENT AND DONOR CHARACTERISTICS DETERMINE OUTCOME AFTER REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, Vol. 93 (pp 354-354)
- . BLOOD, Vol. 110(11) (pp 103A-103A)
- High-dose immune immunoablative therapy and autologous stem cell transplantation in severe resistant Crohn's disease: profound response for 18 months followed by treatable relapse. BONE MARROW TRANSPLANTATION, Vol. 37 (pp S341-S341)
- Successful myeloablative allogeneic haemopoietic stem cell transplantation in a patient with end-stage renal failure on haemodialysis. BONE MARROW TRANSPLANTATION, Vol. 37 (pp S350-S350)
- Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukaemia in second remission: a British Society of Bood and Marrow Transplantation Registry study. BONE MARROW TRANSPLANTATION, Vol. 37 (pp S9-S10)
- Thalidomide maintenance following high dose therapy in multiple myeloma: A UK myeloma forum phase 2 study.. BLOOD, Vol. 106(11) (pp 190A-190A)
- Thalidomide maintenance following high dose therapy in multiple myeloma: A UK myeloma forum phase 2 study.. BLOOD, Vol. 102(11) (pp 691A-691A)
- Il-7 and therapy-induced lymphopenia in RA. ANNALS OF THE RHEUMATIC DISEASES, Vol. 62 (pp 164-164)
- Relapsing precursor B-ALL presenting as CD-10 positive isolated extramedullary lymphoma.. BLOOD, Vol. 94(10) (pp 219B-219B)
- . Journal of Neurology
- Grants
-
- NIHR Efficacy & Mechanistic Evaluation (EME), Health technology Assessment (HTA), Research for Patient Benefit (RfPB)and Biomedical Research Centre (BRC)
- Accelerating Clinical Trials (ACT)/DIDACT Foundation, to support 91探花 Teaching Hospitals NHS Foundation Trust within the IMPACT and TAP Clinical Trials Networks.
- 91探花 Hospitals Charity (SHC).
- Blood Cancer UK (BCUK, formerly called Bloodwise/Leukaemia and Lymphoma Research/Leukaemia Research Fund).
- Cancer Research UK (CRUK).
- Myeloma UK Research Grant Programme.
- Macmillan Cancer Support.
- Health Foundation SHINE Award.
- Healthcare Quality Improvement Partnership.
- Kay Kendall Leukaemia Fund (KKLF).
- Weston Park Hospital Cancer Appeal.
- Arthritis Research Campaign (ARC).
- National Institutes of Health (NIH)/National Cancer Institute (NCI) of USA.
- National Health & Medical Research Council (NHMRC) of Australia.
Postgraduate awards
- Health Service Journal/Nursing Times winner Best Cancer Care Team Award 2014 (with Prof Diana Greenfield for Late Effects Service).
- Anthony Nolan Clinical Supporter of the Year Award 2016.
- , winner of 鈥楾he Future NHS Award鈥 to Professor Basil Sharrack and Professor John Snowden.
- , with Richard Burt.
- Teaching activities
-
- I have been actively involved in teaching and lecturing in undergraduate medicine locally, nationally and internationally.
- Examiner for BMedSci students, University of 91探花.
- Clinical co-supervisor and personal tutor for doctorate (PhD and MD) students at University of 91探花 and UCL.
- Module Co-Lead for MSc(Res) in Translational Oncology (Cancer Diagnosis and Treatment), University of 91探花.
- Examiner for MD/PhDs at 91探花, and external at University of Birmingham, Newcastle University, and University of Oxford.
- Educational supervision of postgraduate specialist training of numerous specialist trainees through the Membership of Royal College of Physicians and Pathologists examinations.
- Examiner for the Royal College of Pathologists.
- Professional activities and memberships
-
91探花 Teaching Hospitals NHS Foundation Trust (STHFT)
- Director of Blood and Marrow Transplant & Cellular Therapy Programme (2002-25).
- Lead Clinician for Haemato-Oncology, STHFT Cancer Services Steering Group (2005-07) and Cancer Executive (2002-05).
- Lead Clinician in Haematology Late Effects Service (2008-25).
91探花 (TUoS) and University College London (UCL)
- Honorary Professor, Department of Oncology & Metabolism, now Division of Medicine, TUoS (from November 2013).
- Honorary Reader, Department of Oncology, TUoS (2010-2013).
- Honorary Clinical Professor, Department of Haematology, The Cancer Institute, UCL (2016-25).
Regional NHS Cancer Roles
- Lead Clinician, Network Site Specific Group (NSSG) for Haemato-Oncology (2007-10), and acting chair/vice-chair of NSSG (2014-15).
- Chair, NSSG Working Party for the Haemato-Oncology Diagnostic Service (2005-07).
- Co-Lead Clinician for Haematology-Oncology in the NHS England Genomic Laboratory Hub (GLH) for North-East & Yorkshire (NEY) region (2019-2025).
National roles and responsibilities
- National Cancer Research Institute (NCRI) Clinical Studies Group (CSG) in Haematological Oncology: Member by appointment (2008-17) and Chair of the Supportive Care, Transfusion & Late Effects Working Party (2015-17), Member of Aplastic Anaemia Working Group (2017-19).
- National Confidential Enquiry into Patient Outcomes and Death (NCEPOD), Member of Expert Working Group for Systemic Anti-Cancer Chemotherapy, from 2006 until publication of report 鈥Systemic Anti-Cancer Therapy: For better, for worse?鈥 in 2008.
- UK Myeloma Forum Executive, Elected Member, 2009-15.
- Chair (2016-20), and Member of NHS England Clinical Reference Group (CRG) for National Specialised Commissioning of BMT Services (2011-2024).
- Chair of the National Clinical CAR-T Panel (NCCP) for acute lymphoblastic leukaemia (2018-19).
- BSBMTCT Executive Committee Member (elected) 2012-2015, Secretary (elected) 2015-18, President-elect (elected) 2019-20, and then President, 2021-22, Past President, 2023-24.
- Member, UKNEQAS Leucocyte Immunophenotyping Steering Committee 2014-present.
- Co-Lead Clinician for Haemato-Oncology of the North East & Yorkshire region Genomic Laboratory Hub (GLH) 2019-25.
- NICE and other NHS related organisations
- Expert clinical member of NICE Guideline Development Group in Myeloma (NG35), 2014-15.
- Clinical Lead, NICE IOG for Haematological Cancers NG47, 2015-16.
- Clinical Co-Lead for COVID-19 rapid NICE Guidance in HSCT (NG164), 2020-21.
- Healthcare Improvement Scotland: Scottish Health Technology Guidance (SHTG) Autologous haematopoietic stem cell transplant for patients with highly active relapsing remitting multiple sclerosis not responding to high efficacy disease modifying therapies (as expert advisor) Published date: October 2019
- Health Technology Wales: Expert Consultation: Autologous haematopoietic stem cell transplantation to treat people with previously treated relapsing remitting multiple sclerosis (EAR019) (as expert advisor). Publication date July 2020
- UK Stem Cell Strategic Forum 鈥楢 ten-year vision for stem cell transplantation鈥. Publication date July 2022. As President of BSBMTCT, I was an integral member of the UK Stem Cell Strategic Forum report, sponsored by NHSBT and supported by Anthony Nolan.
International roles and responsibilities
- Secretary to the European Society for Blood and Marrow Transplantation EBMT (2020-24)
- Chair of the EBMT Autoimmune Diseases Working Party (2016-20), having been Secretary (2010-16).
- EBMT JACIE Committee, as Chair (2015-20) and Medical Director (2012-16).
- JACIE Committee Chair (from April 2015-July 2020) & JACIE Medical Director (2012-16).
- Worldwide Network for Blood and Marrow Transplantation (WBMT) Executive Member (2015-24).
Other Working Parties and Guidelines Groups
- EBMT Transplant Complications Working Party (TCWP) and Severe Aplastic Anaemia Working Party (SAAWP).
- BSH/UKMF Myeloma Guidelines Group (Lead in Supportive Care and Long Term Monitoring Guidelines).
- BSH Aplastic Anaemia Guidelines Group 2014-present.
Scientific Organising Committees, Scientific Journal Editorship and Peer Review Work
- Scientific/organising committee membership e.g. many Annual EBMT Congresses and Educational Events & and BSBMTCT educational and scientific days.
- Associate Editor, Current Research in Translational Medicine (2013-present), Associate Editor Frontiers in Immunology specialty section 鈥楢lloimmunity and Transplantation鈥 (2021-).
- Editorial Board Member, Blood Advances (2021-present), International Journal of Laboratory Haematology (2006-2021).
- Guest Editorships, Frontiers in Immunology Special Edition on 鈥楤iomarkers in Graft versus Host Disease鈥 2019-20, Clinical Medicine (Journal of the Royal College of Physicians of London) for Haematology CME 2018, Current Opinion in Supportive and Palliative Care 2017 special edition on Haematology.
- Peer reviewer for scientific journals, conference abstracts and international, national and local grant applications.
- Peer reviewer for University Professorship promotions.
Clinical Trials Networks and Committees
- Principal Investigator for Clinical Trials Networks (CTNs):
- Cure Leukaemia Therapy Acceleration Programme (TAP, funded 2020-22).
- DIDACT Foundation IMPACT BMT CTN (funded 2023-26).
- Membership of Trial Management Groups (TMG, Data Monitoring and Ethics Committee (DMEC) and Trial Steering Groups (TSG) for many clinical trials.
Media and related work
- Radio and TV as an expert opinion on haemato-oncology and stem cell transplantation, including collaborative work on Haematopoietic Stem Cell Transplantation in Multiple Sclerosis was featured increasingly in media leading to a BBC Panorama documentary 鈥Can You Stop My MS?鈥&苍产蝉辫;aired in 2016 to estimated 2.4 million live, with subsequent broadcast interview coverage and other on-line coverage reaching an estimated 180 million worldwide.
- Also featured in many national newspapers and their on-line versions.
- Examples of invited lectures, chairing and organising committees for last 10 years
2016
- Organiser, Invited speaker, EBMT 鈥楨ducational Meeting of Autoimmune Diseases Working Party鈥, Berlin, January 2016.
- Invited Speaker, Autoimmune Diseases Meeting, Porto, Portugal, January 2016.
- Organiser, Invited Speaker, Abstract Reviewer, Sessional Chair, Annual EBMT Meeting, Valencia, April 2016.
- Invited Speaker, XXXVI World Congress of the International Society of Hematology hosted by the British Society for Haematology, Glasgow, April 2016.
- Invited Speaker, EBMT Highlights, Jeddah, Saudi Arabia, May 2016.
- Invited Speaker, Uppsala University, Sweden, May 2016.
- Invited Speaker, Department of Neurology, Oxford University, June 2016.
- Invited Speaker, Myeloma UK Symposium, Birmingham, September 2016.
- Organiser, Invited speaker, BSBMT Annual Educational Meeting, London, November 2016.
- Organiser, Invited speaker, EBMT 鈥楨ducational Meeting of Autoimmune Diseases and Severe Aplastic Anaemia Working Parties鈥, Paris, November 2016.
- Organiser, Invited speaker, 鈥楲ate Effects in Cancer Survivors鈥, Royal College of Physicians of London, November 2016.
- Invited Speaker, Autoimmunity and Immunodeficiency Diseases Conference, Moscow, Russia, December 2016.
2017
- Invited speaker and session chair, Tandem Meeting of the American Society for Blood and Marrow Transplantation (ASBMT) and Centre for International Bone Marrow Transplant Research (CIBMTR), Orlando, FL, USA, February 2017.
- Organiser, Invited Speaker, Abstract Reviewer, Sessional Chair, Annual EBMT Congress, Marseille, March 2017.
- Organiser, Invited Speaker, NCRI Haemato-oncology Annual Trials Day, May 2017.
- Invited Speaker, 鈥業nflammation, breaking down Silos鈥, Oxford University, June 2017.
- Invited Speaker, University of Jordan, October 2017.
- Organiser, Invited speaker, BSBMT Annual Educational Meeting, London, November 2017.
- Organiser, Invited speaker, EBMT 鈥楨ducational Meeting of Autoimmune Diseases and Inborn Errors Working Parties鈥, Newcastle, November 2017.
2018
- Invited Speaker, Annual ECCO Congress, Vienna, February 2018.
- Organiser, Invited Speaker, Abstract Reviewer, Sessional Chair, Annual EBMT Congress, Lisbon, March 2018.
- Invited speaker, BSBMT Annual Scientific Meeting, London, May 2018.
- Invited Speaker, EBMT Highlights, Riyadh, Saudi Arabia, May 2018.
- Invited Speaker, EBMT Highlights, Delhi, India, May 2018.
- Organiser, Invited speaker, EBMT International Training Course in BMT, September, 2018.
- Organiser, Invited speaker/chair, BSBMT Annual Educational Meeting, London, October 2018.
- Invited Speaker, UKE Hamburg-Eppendorf, Germany, October 2018.
- Invited Speaker, Myelin Meeting, Leipzig, Germany, October 2018.
- Invited speaker, Royal College of Physicians, London, October 2018.
- Organiser, Invited speaker, EBMT 鈥楨ducational Meeting of Autoimmune Diseases and Severe Aplastic Anaemia Working Parties鈥, Florence, November 2018.
2019
- Invited speaker, Royal Society of Medicine, London, March 2019.
- Organiser, Invited Speaker, Abstract Reviewer, Sessional Chair, Annual EBMT Congress, Frankfurt, March 2019.
- Invited speaker, British Society for Cell and Gene Therapy (BSCGT) Annual Meeting, 91探花, UK, June 2019.
- Invited speaker, 61st National Congress of the Spanish Hematology and Hemotherapy Society and 35th National Congress of the Spanish Society of Thrombosis and Hemostasis, Valencia, Spain, October 2019.
- Invited speaker, COSTEM (Controversies in Stem Cell Transplantation) Meeting, Berlin, Germany, October 19-21, 2019.
- Organiser, Invited speaker, EBMT 鈥楨ducational Meeting of Autoimmune Diseases Working Party鈥, Berlin, Germany, October 31-November 1, 2019.
- Invited speaker, international conference 鈥淪tem cell transplantation for treatment of autoimmune diseases: sharing the experience鈥, Moscow, November, 2019.
- Invited speaker, organiser, national conference of the Intercollegiate Committee on Haematology 鈥淯pdates, Controversies, Uncertainties鈥, Royal College of Pathologists, London, December 17, 2019.
2020
- Invited speaker 4th French International Symposium on CAR T Cells, Faculty of Medicine and Lille University Hospital, Lille, France, January 2020.
- Organiser, invited Speaker, Abstract Reviewer, Sessional Chair, Annual EBMT Congress, Madrid, re-scheduled as virtual meeting to August 31-September 2, 2020.
- Organiser, session chair, EBMT 鈥楨ducational Meeting of Autoimmune Diseases Working Party鈥, Virtual Conference, September 24-25, 2020.
2021
- Organiser, invited Speaker, Abstract Reviewer, Sessional Chair, Annual EBMT 鈥榁irtual鈥 Congress, March 14-17 2021.
- Organiser, session chair, EBMT 鈥楨ducational Meeting of Autoimmune Diseases Working Party鈥, Virtual Conference, September 23-24, 2021.
- Invited speaker and session chair, 鈥楨BMT Covid-19 Summit鈥, Virtual Conference, June 29 鈥 July 1, 2021.
- Invited speaker (virtual), Departments of Haematology and Neurology, Leeds Teaching Hospitals, September 21, 2021.
- Organiser, session chair, EBMT 鈥楨ducational Meeting of Autoimmune Diseases Working Party鈥, Virtual Conference, September 23-24, 2021.
- Invited speaker, UK Primary Immunodeficiency Network (UKPIN) Meeting, 91探花, November 2, 2021.
2022
- Invited speaker MS Academy - Live Webinar (with Prof Basil Sharrack) 鈥楿K stem cell transplantation in MS (the StarMS trial), January 27, 2022.
- Invited online lecture to Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California, Irvine, February 9, 2022.
- Invited speaker (online) University College Dublin Centre for Arthritis Research Seminar, February 18, 2022.
- Organiser, Invited Speaker, Sessional Chair (online), 9th Annual ECTRIMS Focused Workshop on Autologous haematopoietic stem cell transplantation for treatment of MS and related diseases, March 10-11, 2022.
- Organiser, invited Speaker, Abstract Reviewer, Sessional Chair, Annual EBMT 鈥榁irtual鈥 Congress, March 19-23, 2022.
- Invited Speaker, Northern Connections MS Meeting, Edinburgh, The Royal College of Physicians of Edinburgh, June 10, 2022.
- Invited speaker, 30th Congress of the Polish Society of Haematology and Transfusion Medicine, September 8-10, 2022.
- Invited speaker, MS At the Limits Meeting, Edinburgh, Royal College of Physicians of London, September 19, 2022.
- Organiser, session chair, EBMT 鈥楨ducational Meeting of Autoimmune Diseases Working Party鈥, Royal College of Pathologists, London, September 24-25, 2022.
- Organiser, North East & Yorkshire Genomic Medicine Service Haemato-Oncology Symposium, October 10, 2022.
- Organiser, Chair, BSBMTCT Annual Educational Meeting, London, November 1, 2022
2023
- Organiser, Invited Speaker, Sessional Chair, The 3rd International Symposium on Stem Cell Treatment in Multiple Sclerosis 鈥 SITraN, 91探花, 20 January 2023
- Organiser, Invited Speaker, Sessional Chair, Annual EBMT Congress, Paris, April 23-26, 2023.
- Invited virtual lecture to New York Medical College, Westchester Medical Center, Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, April 10, 2023.
- Invited virtual lecture at the Florey Institute Symposium, 91探花, 27 April, 2023.
- Invited online lecture to 1st Jordanian International Convention of Transfusion Medicine and Hematopoietic Stem Cells, May 6, 2023.
- Invited Speaker, EBMT Midterm Meeting on Immunedysregulatory, Autoinflammatory and Autoimmune Diseases, Brescia, Italy, June 22-24, 2023.
2024
- Sessional Chair, Annual EBMT CAR-T Meeting, Valencia, Spain, February 15-17, 2024.
- Organiser, Invited Speaker, Sessional Chair, Annual EBMT Congress, Glasgow, UK, April 14-17, 2024.
- Invited Speaker, British Society for Haematology (BSH) Annual Scientific Meeting, Liverpool, UK, April 27-30, 2024.
- Invited speaker and session chair, EBMT Joint Educational Meeting of Cellular Therapy & Immunobiology Working Party and Autoimmune Diseases Working Party, Milan, Italy, October 9-11, 2024.